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Purpose: Allergen-specific immunotherapy (AIT) is the only curative treatment for allergic diseases, but a few allergic patients re-
ceive AIT. In this multicenter cross-sectional study, we aimed to explore patient and physician perspectives on AIT through a 
questionnaire survey.
Materials and Methods: Allergic patients who received subcutaneous immunotherapy for at least 1 year were asked to answer a 
questionnaire developed by an expert panel of allergen and immunotherapy workgroup in Korea. 
Results: A total of 267 patients (adults, 60.3%) with allergic rhinitis (91.4%), asthma (42.7%), or atopic dermatitis (20.2%) from re-
ferred hospitals completed the survey. Among patients and physicians, respectively, the overall rates of satisfaction with AIT for al-
lergic rhinitis were 86.4% and 83.3% (kappa agreement=0.234, p<0.001), and those for asthma were 85.3% and 72.9% (kappa agree-
ment=0.373, p<0.001). Moreover, pediatric asthmatic patients reported a significantly higher satisfaction rate than adult asthmatic 
patients after AIT (p=0.040). Symptom severity (p<0.001, respectively) and drug use for allergic rhinitis and asthma decreased after 
AIT. However, there was no significant difference in satisfaction rates between children and adults in allergic rhinitis (p=0.736). In-
terestingly, 35.7% and 35% of allergic rhinitis and asthma patients, respectively, reported experiencing improvement in their symp-
toms within 6 months of starting AIT.
Conclusion: In this study evaluating the perspectives of patients and physicians on AIT, the majority of patients were satisfied 
with the efficacy and safety of AIT, but not its cost. AIT should be recommended for AR and allergic patients.
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INTRODUCTION
Since Leonard Noon and John Freeman reported the effect of 
prophylactic inoculation of grass pollen in hay fever patients 
in 1911, allergen-specific immunotherapy (AIT) has been 
used to treat allergic diseases in clinical practice for more than 
100 years.1 It is well known that AIT can reduce symptoms 
and medication scores,2,3 alter the natural course of allergic 
diseases4,5 and prevent disease progression from allergic rhi-
nitis to asthma6,7 as well as new sensitization.8,9 However, rela-
tively long treatment duration, high cost, and frequent hyper-
reactivity reactions, including anaphylaxis, can be hurdles to 
choose AIT. 
Although AIT is a well-established, effective therapeutic 
modality for treating allergic disease, the use of AIT is not 
widely used in most countries. A minor portion (2–9%) of al-
lergic patients in the United States have been treated with AIT 
according to previous reports,10,11 and only 36.2% of patients 
recommended AIT by their doctors doctors eventually under-
went AIT.12 This seems to suggest a lack of education and un-
derstanding of AIT among both patients and doctors. Demoly, 
et al.13 reported that about 50% of patients recognized AIT as a 
therapeutic option, of whom 14% had negative opinion there-
of. However, once AIT is started, approximately 60% of pa-
tients are satisfied with it. Among doctors, less than 50% of 
general practitioners were aware of the exact placement of 
AIT, and almost all of them wanted detail information about 
AIT in Italy.14,15 Several aspects of AIT in controlled studies 
have been extensively investigated, including clinical effica-
cy,16-18 tolerability,19 and effects on health-related quality of life 
(QoL);20-22 however, a few studies addressing patient and phy-
sician perspectives on AIT have been published, especially in 
Korea. 
Accordingly, this multicenter cross-sectional study aimed 
to explore patient and physician satisfaction with the efficacy, 
safety, and economic parameters of AIT through a question-
naire survey: this survey addressed symptom changes, medi-
cation use, economic aspects, side effects, and satisfaction 
rate among allergic patients, as well as changes in disease se-
verity based on international guidelines. 
MATERIALS AND METHODS 
Patients
A total of 273 patients with allergic rhinitis, allergic conjuncti-
vitis, allergic asthma, and/or atopic dermatitis were recruited 
from 10 secondary or tertiary hospitals around Korea between 
April 2017 and July 2018 in this study. Inclusion criteria were 
patients who gave written informed consent and received AIT 
to house dust mites, tree/grass/weed pollen, animal dander, 
or fungi for at least 1 year, regardless of AIT methods and 
manufacturing companies. Of the 273 patients, only six re-
ceived sublingual immunotherapy (SLIT) for their allergic 
disease and were excluded from the study. The study protocol 
was approved by the institutional review boards of each hos-
pital (AJIRB-MED-SUR-17-159, Ajou University Hospital). 
Survey
The questionnaire was developed by an expert panel from the 
Korean Academy of Asthma, Allergy and Clinical Immunolo-
gy (KAAACI) on the basis of experience and literature review. 
After a literature search for perspectives of AIT, workgroup 
members made a draft of this study. For each question, re-
sponses and comments from the workgroup members were 
collected and synthesized into a draft manuscript that was re-
circulated until consensus was reached. The questionnaire 
consisted of 15 items for patients and 10 items for physicians. 
The patient questionnaire included demographics, percep-
tion, expectation, side effects, and satisfaction on a 5-point 
Likert scale (much improved/improved/no difference/aggra-
vated/much aggravated; excellent/good/fair/poor/very poor; 
very favorable/favorable/neutral/unfavorable/very unfavor-
able). The physician questionnaire included allergic status, 
AIT products, and changes in disease severity based on inter-
national guidelines. The questionnaire items for patients and 
physicians are presented in the Supplementary Materials 
(only online). 
Statistical analysis
All analyses were carried out using SPSS 22.0 (IBM Corp., Ar-
monk, NY, USA). Descriptive statistics were used to analyze 
demographic and clinical data obtained from the patients’ 
and physicians’ responses to the questionnaire. Continuous 
variables are expressed as means±SD and categorical vari-
ables are expressed as percentage. The clinical data were 
compared among age groups using the chi-square test or 




A total of 267 patients who received subcutaneous immuno-
therapy were analyzed in this study. Enrolled patients consist-
ed of 161 (60.3%) patients treated at the Department of Inter-
nal Medicine and 106 (39.7%) treated at the Department of 
Pediatrics. The mean age was 25.6±15.4 years, and 133 (49.8%) 
were male. AIT was most frequently prescribed to patients in 
their 10s; it was rarely prescribed to patients in their 60s. In 
addition, 79.0% of patients had a family history of allergic dis-
ease, and 10.2% of patients had a previous AIT history. Most 
patients (69.6%) had heard about AIT by general hospital phy-
sicians; however, only 5.9% of allergic patients had heard 
about AIT by general practitioners. 
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Allergic rhinitis (91.4%) was the most common disease to 
be treated by AIT, followed by asthma (42.7%) and atopic der-
matitis (20.2%). Their mean duration of AIT was 27.3±15.0 
months. Moreover, 91.6% of patients reported that they had 
good adherence to AIT, and these data were correlated with 
that of the doctors’ views (kappa agreement=0.356, p<0.001). 
Detailed data on the patient characteristics and immunother-
apy-related factors are shown in Table 1. 
Changes in symptoms and disease severity after AIT
After more than 1 year AIT of treatment for asthma, most pa-
tients reported a better than ‘improved’ state in their daytime 
symptoms (91.0%), nighttime symptoms (92.8%), short-acting 
beta-agonist use (82.4%), asthma attack (87.2%), and QoL 
(90.5%) (Fig. 1A). Physician indicated in the questionnaire on 
allergy symptoms and medication use that disease severity 
dramatically decreased after AIT for asthma (intermittent 
from 7.9% to 63.4%, mild persistent from 38.6% to 28.7%, 
moderate persistent from 46.5% to from 6.9%, and severe per-
sistent 6.9% to 1.0%, p<0.001) (Fig. 1C). 
For patients with rhinitis, there were improvements in 
symptoms, including rhinorrhea (92.3%), nasal obstruction 
(87.2%), sneezing (88.0%), itching (82.2%), eye itching (80.1%), 
and eye redness (76.1%) (Fig. 1B), as well as disease severity 
(mild intermittent from 0% to 64.8%, moderate-severe inter-
mittent from 8% to 20.2%, mild persistent from 10.8% to 14.1%, 
and moderate-severe persistent from 81.2% to 0.9%; p<0.001), 
(Fig. 1D). 
Interestingly, about 15% of patients reported symptom im-
provements within 3 months after starting AIT, and almost 3 
out of 4 patients reported that their symptoms were dimin-
ished within 1 year after starting AIT (Fig. 2). However, wheth-
er patients had only one of rhinitis or asthma or both diseases 
did not affect satisfaction with AIT among patients and their 
physicians.
Changes in medication use after AIT
Prescription rates were evaluated for individual drugs in the 
questionnaire for physicians. Before starting AIT, ICS, beta-
agonists, LTRA, and theophylline were administered to 79.8, 
61.1, 57.5, and 2.9% of the asthmatic patients, respectively; 
however, the prescription rates dramatically dropped to 49.1, 
37.5, 29.7, and 1%, respectively, after AIT treatment (Fig. 3A). 
Drug prescription rates were also investigated in patients 
with allergic rhinitis. The prescription rates of intranasal corti-
costeroid, antihistamines, and LTRA were 82.5, 89.8, and 
66.9%, respectively, before starting AIT. The prescription rates 
were significantly decreased to 35.6, 48.8, and 32.8%, respec-
tively, after AIT (Fig. 3B). 
Medical and socioeconomic aspects of AIT 
As for advantages of AIT, disease aggravation and drug de-
mand were decreased such that patients reported a better 
than ‘good’ state in 84.3% and 83.0% of patients, respectively, 
and 79.2% of patients were in a better than ‘good’ state with 
respect to adverse reactions to AIT. Regarding economic as-
pects of AIT, 78.7% and 83.2% of patients reported a better 
than ‘good’ state for time consumption with AIT treatment 
and methodologic discomfort of AIT; however, 53.6% of pa-
tients described burden with the cost of AIT (Fig. 4). In addi-
tion, the rates of overall satisfaction with AIT higher than 
‘good’ were 85.3% and 86.4%, respectively, in patients with 
asthma and allergic rhinitis (Fig. 5), and these were corre-
sponded with those results of their physicians (kappa agree-
ment=0.234, p<0.001 in allergic rhinitis and kappa agree-
ment=0.373, p<0.001 in asthma). Interestingly, the rates of 
satisfaction with AIT for asthma tended to be higher in pa-
tients than in physicians.
Moreover, 91% of patients wanted to continue AIT, and 
Table 1. Demographic- and Immunotherapy-Related Characteristics of 
Patients in This Study
 Variables n=267 (%)








Sex, male 133 (49.8)
Family history of allergic diseases 211 (79.0)
Indicated diseases for AIT (duplicated)
Asthma 114 (42.7)
Allergic rhinoconjunctivitis 244 (91.4)
Atopic dermatitis 54 (20.2)
Previous AIT history 27 (10.2)
Mean duration of AIT (month) 27.3±15.0 (12–90)
Information source of AIT
General hospital physician 165 (69.6)
General practitioner 14 (5.9)
Acquaintances 33 (13.9)
Internet/media 19 (8.0)
Other patients 1 (0.4)
Others 5 (2.1)





Very poor 3 (1.1)
AIT, allergen-specific immunotherapy.
Family history represents to have allergic diseases in the direct blood rela-
tives of the patient. Data are presented as a mean±SD (range) or number 
(percentage).
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88.7% were willing to recommend AIT for other allergic pa-
tients. The results demonstrated that AIT can be a safe and ef-
fective therapeutic option for allergic patients in both medical 
and economic aspects, except for its cost.
The efficacy of AIT according to age groups
The efficacy of AIT was assessed in the pediatric and adult 
groups. Although parameters of allergic rhinitis/asthma 
symptoms or adverse reactions were not different between 
the groups (data not shown), there was a significant difference 
in guideline-based disease severity and medication use. The 
proportions of patients with intermittent severity asthma were 













Before AIT                                    After AIT Before AIT                                     After AIT
  Intermittnet      Mild persistent 
  Moderate persistent      Severe persistent
  Mild intermittnet      Mod-severe intermittent 


















Day Sx.        Night Sx.     SABA use      Attack            QoL Rhinorrhea Obstruction Sneezing     Itching          Eye             Eye 
  itching      redness
  Much improved     Improved     No difference
  Aggravated            Much aggravated
  Much improved     Improved     No difference
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Fig. 1. Changes in allergy symptom and severity after AIT. (A) Symptom changes in patients with asthma. (B) Symptom changes in patients with allergic 
rhinitis. (C) Asthma severity change based on the GINA guideline. (D) Allergic rhinitis severity change based on the ARIA guideline. AIT, allergen-specif-





























Fig. 2. Time to symptom improvement after allergen-specific immuno-
therapy.
groups after AIT. The use of inhaled corticosteroids (ICS) 
(28.1% vs. 57.7%), beta-agonists (22.6% vs. 44.6%), and leukot-
riene receptor antagonists (LTRA) (9.4% vs. 36.8%) were sig-
nificantly less frequent in the pediatric group than in the adult 
group. Moreover, the prescription rates of antihistamine were 
quite decreased in pediatric allergic rhinitis patients com-
pared to those in adult patients (Table 2). 
The overall rates of satisfaction with AIT for asthma were 
significantly higher in the pediatric group than in the adult 
group (1.83±0.66 vs. 1.64±0.77, p=0.040). However, such re-
sults were not observed in allergic rhinitis patients who re-
ceived AIT (Table 2). Sex, adherence to AIT, initial disease se-
verities, and associated diseases did not affect satisfaction 
with AIT in both asthma and rhinitis patients.
Taken together, our results showed that AIT might reduce 
allergy symptoms, medication use and disease severity based 
on the GINA or ARIA guidelines in Korean patients with asth-
ma or allergic rhinitis. 
DISCUSSION
In this cross-sectional study, we aimed to evaluate patient 
perspectives on AIT together with those of their physicians, 
and found excellent satisfactions with AIT in regarding to its 
efficacy and time-consuming and methodologic difficulties 
in both groups with good correlation. We also clearly showed 
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Fig. 3. Changes in drug prescription patterns after AIT. (A) Prescription patterns after AIT in patients with asthma. (B) Prescription patterns after AIT in 
patients with allergic rhinitis. AIT, allergen-specific immunotherapy; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonists; INS, intra-
nasal corticosteroid.















































that about three-quarter of the patients experienced symptom 
improvement within a year after AIT in this study.
Although many surveys of prescription patterns in AIT have 
been published,23,24 studies regarding perspectives or satisfac-
tion with AIT are extremely rare, especially in Korea. This 
study had some heterogeneity in disease patterns, hospital 
settings, ages, and products for AIT and the specialties of phy-
sicians due to its retrospective design. Despite this heteroge-
neity, it is interesting that the overall rate of satisfaction with 
AIT was more than 80% for asthma or allergic rhinitis patients, 
moreover, it was more than 70% for physicians. This result is 
in line with those of previous studies performed in Italy and 
Spain.19,20 The rates of patient and physician satisfaction with 
AIT were 74/100 and 78/100, respectively, using VAS scores, 
and showed a significant similarity between them.25 The Satis-
faction Scale for Patients Receiving Allergen Immunotherapy 
(ESPIA) totaled 69.2 points on a 0–100 scale after sublingual 
grass pollen immunotherapy.26 Although the methods for 
evaluating the overall rate of satisfaction with AIT were not 
similar between studies, AIT appeared to be an excellent ther-
apeutic option meeting the expectations of allergic patients 
and physicians. In contrast, the most unsatisfactory part had 
answered the cost of AIT. More than 50% of patients answered 
fair or worse opinions in that question. 
Another interesting result of this study was that the rate of 
satisfaction with AIT was higher in pediatric asthmatics than 
in adult asthmatics. While patient age does not seem to be a 
limitation to AIT, the efficacy of AIT according to age groups is 
still debatable. Asthma is a chronic inflammatory disease that 
leads to irreversible changes in the airway. Therefore, it would 
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be advisable to start AIT earlier in the disease process. Our 
data showed no differences in allergy symptoms between pa-
tients of ages less than 15 years and those older than 15 years, 
but showed a significant difference in guideline-based dis-
ease severity and medication use after AIT, especially in asth-
matics. Previous studies have reported similar results as ours. 
SLIT with house dust mite extracts seems to be as effective in 
school-age children and adolescents as in adults; however, 
the degree of reduction in medication use tended to be higher 
in the young age group than in the adolescent group.27 Inter-
estingly, a significant difference in disease severity was found 
only in asthma, but not in allergic rhinitis. Airway remodeling 
such as collagen deposition could prominently occur in sub-
optimally treated or untreated asthma, in contrast, those fea-
tures are not prominent in allergic rhinitis. We thought the 
above difference may attribute to our results in asthma and 
rhinitis. Moreover, some discrepancies in satisfaction rates 
with AIT for asthma between patients and physicians may 
have been attributed to the lack of objective monitoring tools 
such as pulmonary function tests to patients. Further studies 
are needed to confirm our findings. 
Patients should be educated about AIT before the start of 
AIT because AIT requires a long treatment duration and 
sometimes causes hypersensitivity reactions. In this study, 
only 5.9% of the patients had heard about AIT from general 
practitioners. The Internet, media, or acquaintances were im-
portant sources of information on AIT. This could disseminate 
incorrect knowledge about AIT to many allergic patients. This 
finding was also in line with those of previous studies con-
cerning the sources of information on AIT.13,15,25 Approximate-
ly 30% of patients expected immediate therapeutic effects 
from AIT, and about 20% of the patients wanted the treatment 
to be performed for a short period of time.25 Our results can 
explain the reasons why AIT is not frequently offered to pa-
tients and why many patients hold misconceptions about AIT 
in Korea. We should consider the education of general practi-
tioners and the use of multimedia for better understanding 
and more prescriptions of AIT in Korea. 
AIT significantly decreased all clinical symptoms in patients 
with asthma or allergic rhinitis as reported in previous stud-
ies.28,29 More than 80% of patients reported an ‘improved’ or 
‘much improved’ state in regarding to clinical symptoms after 
AIT. In addition, disease severity, an objective parameter, was 
also reduced after AIT in many patients. In this study, 81.2% of 
allergic rhinitis patients showed a moderate to severe persis-
tent state before AIT; 64.8% of the patients changed to mild 
intermittent state; and only 20.2% of the patients showed a 
moderate to severe intermittent state after AIT. Similarly, 7.9% 
of intermittent asthma patients turned to 63.4% after AIT. 
These results are also consistent with those of previous studies 
demonstrating that the severity of allergic rhinitis was reduced 
from moderate to severe severity to mild severity in 49.1% of 
patients.26 This study also showed the decreased medication 
prescription rate after AIT in both allergic rhinitis and asthma 
patients. Taken together, AIT might be very effective in im-
proving disease severity and reducing the frequency of medi-
cation use. 
Our survey evaluated the time of symptom improvement. 
About 15% of patients reported symptom improvement with-
in 3 months, more than 30% of the patients within 6 months, 
and 75% of patients within 1 year. It is conceivable that AIT 
can show quick therapeutic effects through early desensitiza-
tion of mast cells within 1 week and production of regulatory 
cytokines, such as IL-10 and TGF-beta, within 6 months.30,31 
Although further studies are needed to confirm our findings, 
time to symptom improvement can help to explain the onset 
timing of AIT to allergic patients. 
Our study has some limitations. First, we only analyzed re-
sults from patients receiving subcutaneous immunotherapy. 
In a previous study in Korea, SLIT was usually prescribed by 
otolaryngologists.32 However, enrolled doctors in our study 
were only from internal medicine and pediatrics. This is the 
reason why the number of patients receiving SLIT was small 
in our study. Secondly, we could not compare the efficacy and 
safety of AIT between AIT products or administration meth-
ods. The questionnaire developed by an expert panel of the 
allergen and immunotherapy workgroup of the KAAACI was 
inadequate for these purposes. Our workgroup is planning to 
compare AIT products in future studies. However, the 
strengths of the present study are that data were collected in 
real-life settings and that relevant data based on current 
guidelines were provided for the management of patients re-
Table 2. Effects of AIT according to Age Groups
Age ≤15 Age >15 Total p value
Asthma severity after AIT 0.004
Intermittent 25 (86.2) 39 (54.2) 64 (63.4)
Mild persistent 3 (10.3) 26 (36.1) 29 (28.7)
Moderate persistent 0 (0) 7 (9.7) 7 (6.9)
Severe persistent 1 (3.4) 0 (0) 1 (1)
Rhinitis severity after AIT 0.794
Mild intermittent 38 (67.9) 100 (63.7) 138 (64.8)
Mod-severe intermittent 10 (17.9) 33 (21.0) 43 (20.2)
Mild persistent 8 (14.3) 22 (14.0) 30 (14.1)
Mod-severe persistent 0 (0) 2 (1.3) 2 (0.9)
Beta-agonist use after AIT 7 (22.6) 29 (44.6) 36 (37.5) 0.044
ICS use after AIT 9 (28.1) 45 (57.7) 54 (49.1) 0.006
LTRA use after AIT (asthma) 3 (9.4) 28 (36.8) 31 (28.7) 0.005
INS use after AIT 20 (42.6) 48 (33.3) 68 (35.6) 0.293
Antihistamine use after AIT 19 (34.5) 82 (53.9) 101 (48.8) 0.018
LTRA use after AIT (rhinitis) 17 (30.4) 40 (33.9) 57 (32.8) 0.730
Overall satisfaction in asthma 1.83±0.66 1.64±0.77 1.71±0.73 0.040
Overall satisfaction in rhinitis 2.99±1.08 2.85±1.27 2.90±1.20 0.736
AIT, allergen-specific immunotherapy; ICS, inhaled corticosteroids; LTRA, leu-
kotriene receptor antagonists; INS, intranasal corticosteroid.
Data are presented as a number (percentage) or mean±SD.
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ceiving AIT, emphasizing the importance of the patient’s point 
of view on AIT. Thirdly, since some children may have sponta-
neous remissions of allergic symptoms as they become older, 
we cannot confirm the superiority of AIT in childhood asthma 
on the basis of the above results. 
In conclusion, in this study evaluating the perspectives on 
AIT in both patients and physicians, the majority of patients 
and physicians were satisfied with the efficacy and safety of 
AIT, except for its cost. Physicians who treat allergic patients 
should recognize the strength and weakness of AIT and rec-
ommend more AIT to allergic patients.
ACKNOWLEDGEMENTS
This work was supported by a grant from the Korean Academy 
of Asthma, Allergy and Clinical Immunology (KAAACI).
AUTHOR CONTRIBUTIONS
Conceptualization: Yoo Seob Shin and Jae-Woo Jung. Data curation: 
Jae-Woo Kwon and Sang Min Lee. Formal analysis: Yoo Seob Shin 
and Ji Hye Kim. Funding acquisition: Sooyoung Lee and Jung-Won 
Park. Investigation: Yoo Seob Shin, Jae-Woo Jung, and Jeong-Hee 
Choi. Methodology: Jae-Woo Jung, Jae-Woo Kwon, and Jung-Won 
Park. Project administration: Yoo Seob Shin. Resources: Ji Hye Kim, 
Sang Min Lee, and Jae-Woo Kwon. Software: Yoo Seob Shin, Jae-Woo 
Jung, and Sooyoung Lee. Supervision: Man Yong Han, Young Min 
Ahn, and Jung-Won Park. Validation: Jeong-Hee Choi and Jae-Woo 
Jung. Visualization: Sooyoung Lee and Sang Min Lee. Writing—origi-
nal draft: Yoo Seob Shin and Jeong-Hee Choi. Writing—review & ed-
iting: Man Yong Han and Young Min Ahn.
ORCID iDs




Jae-Woo Kwon https://orcid.org/0000-0003-1639-3606 
Sooyoung Lee https://orcid.org/0000-0003-1734-4101
Ji Hye Kim https://orcid.org/0000-0003-4677-0513
Sang Min Lee https://orcid.org/0000-0002-9568-2096
Young Min Ahn https://orcid.org/0000-0002-1697-8041
Man Yong Han https://orcid.org/0000-0002-9077-5779 
REFERENCES
1. Noon L. Prophylactic inoculation against hay fever. Int Arch Aller-
gy Appl Immunol 1953;4:285-8.
2. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of spe-
cific immunotherapy in patients with severe perennial allergic 
rhinitis induced by house dust mite: a double-blind, randomized, 
placebo-controlled trial. Clin Exp Allergy 2003;33:1076-82.
3. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect 
of subcutaneous SQ-standardised specific immunotherapy in 
moderate and severe house dust mite allergic asthmatics. Allergy 
2006;61:843-8.
4. Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Høst 
A, et al. Five-year follow-up on the PAT study: specific immuno-
therapy and long-term prevention of asthma in children. Allergy 
2006;61:855-9.
5. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding 
GK, et al. SQ-standardized sublingual grass immunotherapy: con-
firmation of disease modification 2 years after 3 years of treatment 
in a randomized trial. J Allergy Clin Immunol 2012;129:717-25.
6. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, 
Høst A, et al. Specific immunotherapy has long-term preventive 
effect of seasonal and perennial asthma: 10-year follow-up on the 
PAT study. Allergy 2007;62:943-8.
7. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, 
et al. Coseasonal sublingual immunotherapy reduces the devel-
opment of asthma in children with allergic rhinoconjunctivitis. J 
Allergy Clin Immunol 2004;114:851-7.
8. Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir 
Y. Prevention of new sensitizations by specific immunotherapy in 
children with rhinitis and/or asthma monosensitized to house dust 
mite. J Investig Allergol Clin Immunol 2007;17:85-91.
9. Reha CM, Ebru A. Specific immunotherapy is effective in the pre-
vention of new sensitivities. Allergol Immunopathol (Madr) 2007; 
35:44-51.
10. Hankin CS, Cox L, Lang D, Levin A, Gross G, Eavy G, et al. Allergy 
immunotherapy among Medicaid-enrolled children with allergic 
rhinitis: patterns of care, resource use, and costs. J Allergy Clin Im-
munol 2008;121:227-32.
11. Law AW, Reed SD, Sundy JS, Schulman KA. Direct costs of allergic 
rhinitis in the United States: estimates from the 1996 Medical Ex-
penditure Panel Survey. J Allergy Clin Immunol 2003;111:296-300.
12. Anolik R, Schwartz AM, Sajjan S, Allen-Ramey F. Patient initiation 
and persistence with allergen immunotherapy. Ann Allergy Asth-
ma Immunol 2014;113:101-7. 
13. Demoly P, Didier A, Mathelier-Fusade P, Drouet M, David M, 
Bonnelye G, et al. Physician and patient survey of allergic rhinitis in 
France: perceptions on prevalence, severity of symptoms, care man-
agement and specific immunotherapy. Allergy 2008;63:1008-14. 
14. Lombardi C, Canonica GW, Passalacqua G. The perception of al-
lergen-specific immunotherapy among chest physicians: an Ital-
ian survey. Eur Ann Allergy Clin Immunol 2014;46:132-6.
15. Lombardi C, Bettoncelli G, Canonica GW, Passalacqua G. The per-
ception of allergen-specific immunotherapy among Italian gener-
al practitioners. Eur Ann Allergy Clin Immunol 2012;44:80-2.
16. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual im-
munotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; 
12:CD002893. 
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